• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Systemic identification of mutated proteins with frame-shifted from MSI positive colon carcinoma

Research Project

Project/Area Number 14571226
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionKEIO UNIVERSITY

Principal Investigator

FUJITA Tomonobu  Keio University, School of Medicine, Instructor, 医学部, 助手 (20199334)

Co-Investigator(Kenkyū-buntansha) KITAJIMA Masaki  Keio University, School of Medicine, Professor, 医学部, 教授 (90112672)
MATSUZAKI Yuriko  Keio University, School of Medicine, Instructor, 医学部, 助手 (40255435)
KAWAKAMI Yutaka  Keio University, School of Medicine, Professor, 医学部, 教授 (50161287)
KITAGAWA Yuko  Keio University, School of Medicine, Instructor, 医学部, 助手 (20204878)
WATANABE Masahiko  Keio University, School of Medicine, Assistant Professor, 医学部, 専任講師 (80146604)
Project Period (FY) 2002 – 2003
Project Status Completed (Fiscal Year 2003)
Budget Amount *help
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2003: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 2002: ¥1,900,000 (Direct Cost: ¥1,900,000)
KeywordsColorectal cancers with microsatellite instability / frameshift-mutated peptides / immunotherapy / tumor antigen / SEREX / フレームシフトタンパク / TGFBRII
Research Abstract

Colorectal cancers with microsatellite instability (MSI+ CRCs) caused by dysfunction of DNA mismatch repair have unique clinicopathological characteristics including good prognosis with T-cell infiltration in tumor. Previously we demonstrated frame-shifted mutated CDX2, as tumor antigens that induce immune response against MSI+ CRC, by SEREX (serological analysis of recombinant cDNA expression cloning). In this study, the immunogenic proteins with frameshift mutated in the microsatellite of the coding region were screened. We isolated 26 genes from SEREX with two libraries of MSI positive colon cancer tissues and autologus sera, but found no genes reported as MSI target genes and tumor specific genes by RT-PCR. We made recombinant proteins from 8 target genes (TGFBRII, BAX, TCF-4, CASP-5, SEC63, AIM2, OGT, RAD50), which make frame-shifted mutated peptide caused by mismatch repair genes. The presence of IgG antibody against recombinant proteins examined by MSI+ CRCs sera of 13 patients by western blotting and ELISA, but none of them showed positive. However, the tissues with patients had some mutation in the target genes. We reconstructed recombinant protein of TGFBRII, and we performed Western blot analysis using another 4 MSI+ CRCs sera. One serum from patient with TGFBRII mutation reacted with normal and mutated recombinant protein. Therefore, tumor specific peptides generated by MSI may be involved in anti-tumor immune responses, but the abilities of immuno response to proteins with frameshift mutated in MSI may be relatively weak. Further investigation is required to identify the proteins with frameshift mutated in MSI+ CRCs.

Report

(3 results)
  • 2003 Annual Research Report   Final Research Report Summary
  • 2002 Annual Research Report
  • Research Products

    (9 results)

All Other

All Publications (9 results)

  • [Publications] Ito, T: "Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer"International Journal of cancer. 108. 712-724 (2004)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Ishikawa, T: "Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability"Cancer Research. 63. 5564-5572 (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] 藤田知信: "ヒト腫瘍抗原ペプチドの同定法と抗腫瘍免疫応答解析法"Biotherapy. 16. 441-448 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Ito, K., Fujita, T., Akada, M., Kiniwa, Y., Tsukamoto, M., Yamamoto, A., Matsuzaki, Y., Matsushita, M., Asano, T., Nakashima, J., Tachibana, M., Hayakawa, M., Ikeda, H., Murai, M., Kawakami, Y.: "Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer"Int J Cancer. 108. 712-724 (2004)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Ishikawa, T., Fujita, T., Suzuki, Y., Okabe, S., Yuasa, Y., Iwai, T., Kawakami, Y.: "Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability"Cancer Res.. 63. 5564-5572 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Fujita, T., Kawakami, Y.: "Identification of tumor antigens recognized by T cells and their use for analysis of anti-tumor responses"Biotherapy. 16. 441-448 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Ishikawa, T: "Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability"Cancer Research. 63・17. 5564-5572 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Ito, T: "Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer"International Journal of cancer. 108・5. 712-724 (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] 藤田知信: "ヒト腫瘍抗原ペプチドの同定法と抗腫瘍免疫応答解析法"Biotherapy. 16・5. 441-448 (2002)

    • Related Report
      2002 Annual Research Report

URL: 

Published: 2002-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi